![](https://investorshub.advfn.com/uicon/81806.png?cb=1635633872)
Monday, February 11, 2008 4:43:07 PM
Vertex Pharmaceuticals (VRTX) is expected to report Q4 earnings Monday with a conference call scheduled for 5:00 p.m. ET.
Guidance
Analysts are looking for a loss of (66c) on revenue of $67M. The consensus range is (45c) to (90c) for EPS, and revenue of $43M to $102M, according to First Call. Vertex announced that they most likely wouldn't file for approval of Telaprevir in previously untreated Hepatitis-C patients until after 2010. On a positive note, Vertex is looking to get a combination Telaprevir study approved.
Analyst Views
Recently, JMP Securities said the stock has reached a trough and that Vertex will have positive momentum in 2008. They initiated the stock with a Market Outperform and gave the shares a $25 price target. Lazard lowered their target on the shares to $13 from $16, and maintains a Sell rating. They expect competition to increase, with other Hepatitis drugs gaining market share.
http://seekingalpha.com/article/63933-earnings-preview-vertex-pharmaceuticals
Recent VRTX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 08:10:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/02/2024 08:03:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:17:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:05:43 PM
- Vertex Reports Second Quarter 2024 Financial Results • Business Wire • 08/01/2024 08:01:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/01/2024 07:34:43 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/30/2024 07:25:57 PM
- Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain • Business Wire • 07/30/2024 05:10:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2024 08:06:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 08:05:44 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/24/2024 04:27:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/22/2024 05:16:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:13:27 PM
- Santé Canada autorise la commercialisation de TRIKAFTA(MD) (éléxacaftor/tézacaftor/ivacaftor et ivacaftor) chez les personnes atteintes de fibrose kystique âgées de 2 ans et plus présentant certaines mutations rares • PR Newswire (Canada) • 07/15/2024 01:00:00 PM
- Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations • PR Newswire (Canada) • 07/15/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 08:07:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/10/2024 02:27:12 PM
- Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis • Business Wire • 07/02/2024 12:33:00 PM
- Vertex to Announce Second Quarter 2024 Financial Results on August 1 • Business Wire • 07/01/2024 08:05:00 PM
- Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions • Business Wire • 06/21/2024 07:45:00 PM
- Vertex Announces Extended Long-Term Reimbursement Agreement with NHS England for Access to Cystic Fibrosis Medicines KAFTRIO®, SYMKEVI® and ORKAMBI® • Business Wire • 06/20/2024 11:15:00 AM
- Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress • Business Wire • 06/14/2024 07:03:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:11:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:09:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/12/2024 01:56:43 PM
Kona Gold Beverages, Inc. Announces Strategic Initiatives and Corporate Direction Changes • KGKG • Aug 2, 2024 2:00 PM
POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • POET • Aug 1, 2024 9:28 AM
Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM
VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM
Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM
Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM